! "# ! $
-1
-2
!"#$
-3
# &$ '
4
) *+
: !
.
#$%!
% &
'( )'! *+!
# ,
'! ! #! -!
. / 0
1 2( 3
4 5
. / 6 7 8 '9! : ;5 +
.
6 7 < ! %= > ?' 8
*9 .@ ! )'!
#;'A&
- B 4' 5 %',
! *C %D
MVD
Microvessel Density)
(
# #!
%, F 6 7 / .
*;5 + ) : -
F /
*! *; % !
# H ! -!
I'
# J/
K L '!
) N ( F 0
; 30
> # 5 )
- B .@ ! (
30 .@ ! #;'A&
/ Q - - B .
6R S T!
6R U %-
#J'! !
/ . V(
S T! # ' / *' S W%! #J'@ (
W%! %!
X
! # '/ 9' J ' Y %H 0
Z T / T
'
(VEGF: Vascular Endothelial Growth Factor)Z / 6 7
. V(
6R *' I J
F
; [ %
MVD 4\ C
#L % C % %]C > ! ^ [ % W /
(Hot Spot)
' _'
! #( _ % J, !
# 400
%! %!
W ,
%, . ' :
> # 5 MVD
) 2 / 20 (
!
*
%, %@ % 0'! #b-0 &
/ ) 9 / 6 (
. ! : d %D
MVD ' .@ ! > # 5 *! 2 A '! %, )'!
#;'A&
#J;
! ) 001 /
P<0 .(
* @ :
*C 0 F?' 8 )
! > # 5 *
%, %@ % 0'! #b-0 &
/ ) .@ !
#;'A&
( . J5 > # 5 %, )'! # J\ : d d
4' 2! T' 4' 2!
.
$ &% : 1 4\ C #L % C % 1
# '/ 9' J 1
'+, *- . / 01 2 34 ! 01 05 )
2 15 2 - 9 2 9
# ; <
1387 (
: 27 / 5 / 1386
! D EF&
: 29 / 9 / 1386 H I.
: 11 / 10 / 1386
1Z f9 J9 1
I' #/ %,
#_/ ( _0 # J/
0 #_/ ( 6 T H0
) $ %, $ 4 ! # J/
(
g : 0 - K L '!
-
5 -!
)dT : 8012584 - 0511
%!
: 8409612 - 0511
#_' % _5 .9(
sadeghianmh@mums.ac.ir:
%, '0 2
#/
# J/ I' F#_/ ( _0 F
0 #_/ ( 6 T H0
I' #/ %, 3
#_/ ( _0 # J/
0 #_/ ( 6 T H0
) $ %, $ 4 ! # J/
(
'0 4
#_/ ( _0 F# #_/ ( #/ %, 6 T H0
0 #_/ (
, &%
$ 9'
# '$ ! ) % ; /
# Q 98 !
%, .
* A& g %!
J!
%,
9 %@
F
# _ % F
# ' %!
# ./ ! *
F
* , %, 'K dJ5 'K T' : ; = '9
# J!
/ ) 1 .(
> # 5 l ) % ; /
F C C 5
> 4' 2! dJ5 # )'B5 ! †
# 5
> 4' 2! T' . ‡
) 2 .(
%9 C ' 9 W , g %!
_ % F ! > 4' 2! dJ5 # 5 * '5 %! '
) ) @%, %D F
4 / 1
% 000 / 100 . .
%! '
%]C > F / % 0'! ) @ ! > 4' 2! T' # 5 l '/
) 68
%! ' ! #H5 4
/ 3
%
000 / 100 . ) 3 .(
m / &% ) ' 0C 1.
# 'L *\%,
0C W , g %! #5 .9' g%
F .An
Z # &%
1382
. % C% o / 6 7
F./ ! : '!
#_/ ( W )
Z 677 # 5
1057 %
! ! m / &% )' 0 '! ) *C / W , YC 02
/ 4
% &%
89 / 4
% &%
# Y / % /
1
* A5
*C &
. 9L
*7' . / %Cq W , ) %', F
!
*
# , , .T
C %
# 5 #b'-0
! <%& *K 6
#$%
. #;L % C '9! / *K 6 L F C % )
4 .(
Y # J/ '! l '/ . *!
f ( %n
.' '!
.
%'$ 5
# '$ !
*AJ 4 5
#dT - # %!
%L . * @%, 1
@ *+! Z ] %!
Y /
Z T Z 'T
Y
# 2! %A'@ /
*C §
*French-American-British (FAB)
†Acute lymphoblastic leukemia (ALL)
‡Acute myeloblastic leukemia (AML)
§
9, ' r(
J 9 F
# 5 #_'J'TC : b-0 !
*+! )'Js
@ '! % Z & ! MVD
. / W , ; 6 T' *! 2 A )
5 .(
9, F
%bJ .@%0'( %!
#TAL [ % #,% [ % Y'_0 ! !
# t %; .@ !
%, .
*C # uv *! / %!
# *K *! [ % o /
F
4 %8 ! J '
# %@ $ ' ) 9,
JJC .
# J
'! %+L F ! 1
- 2
! JJC '( % 'T'
Z T #9C r' %n ) '! @
# ( ( \
/ .
*'5 / %! J *
%= ' %! %! *_T!
. 1 . ) !
! %! %= 4 5 '! %bJ 4
# '$
Q 98
# / ) 6F5 .(
9( &% %'D ! '5 F
* F
%L # %! tT - : ;5 + 'K %' 5 C . * @%, )
7 - 10 .(
'5 %! 2
F
;
*5
2( 3 ' 4 5
*C f n %
'( %!
# , )'
#T &
f o$ )''; %n
# '$ ! tT - l *! 2 A '! #0 . 4 5 )
11 - 13 (.
.';= %! % 0'! / 6 7 : ' 8 ' 0C
. ! C% '5
) 8 - 10 .(
!
A9 l '/ *! *
w
R ! 0C # 5 F
.$ J/
Y f F ( %! %n '(
# , '! )
# %D *! %=
.
*C / %! *;5 + )
d ! # '/ 9' J J / W
VEGF**
*C
%H 0 A J
# Z T %!
. [ % Z 'T F
*!
' # %!
*
# 5 *! 2 A '!
>
*9 * $ %(
.@ ! ! #;'A&
' 6 7 .
# !
**
@ : An : x . )
[ % '
4\ C (
Z% JC . *! *; =
.@ $ %,
.
-.
/ , 0 *;5 + # *C ?' 8 ) 6 7 . -
/
# Q 98
%, F
!
*! *; %
# H ! -!
I'
# J/
K L '!
) N ( 0 F
* )'!
B #9( '!
-
%'$ 5 )
1376 - 1386 (
#@ C .@ ! *C
J / # '/ 9' J # %! %! I J F
30 .@ !
> # 5
; 30 .@ !
#;'A&
B
! -
*
%, J /
Q -
%, .
#J'5 ! : 2&
'!
I' -! %(
# J/
2
U %- # H ! /
.
/ %, 2
I' o dC Fy'-0 ' z DJ *! g J/
.
*
%, # %! w 7 .
6 : x ! I J
6R F
X 7 W%!
) K )'T'9C '
(H & E)
/ 6 7 %!
DJ *! .
Y' _ '
'! : 2&
F ' - B ' %'r N
# H !
'! %( 5 -!
F
# %!
.@%, %L 1
)'Js
2 6 5 : x
' %'r
'; g %! *C # 5 l ' . - B
* A& FAB
! / J!
F
#J'! ! / 1
- B
' #;'A&
!
* J
* /
#9( '!
%! *C #
#dJ / %@ 6 dJ5 %D - B %',
! / W , F
%, Q - .
;!
Fy'-0 %D # ' . dC .'d'C
* F S T!
#J'@ ( 2
# H ! *& !%
w > . -= *! S # /%! U %- 4
*' %_' /
.
*T>%
;!
F /%!
: *!
24 .
/ H [ : %>
) ' ! _ (
1 r V
)'@ (
# YT , !
;!
Q
! Y_5 d ! # / 6 7 tT - { T$ :
.
# .@ ! .
: % ' %@ ! Z T8 01
/ 0 o'8 R : *! %_
12
* 'L
/ d
X Vr
# '/ '9' J '
W *!
) - )' '!
- '9C %(
! d
%H 0
/ 6 7 VEGF
.
) * @ C *! Z TC ! #
! % : b-0 |%&
:
-Monoclonal mouse antihuman Vascular EndothelialGrowth Factor
-Dacocytomatin , Dennmark, code: M 7273, clone:VG1
X ' %$ *T>%
)'T'9C '
%
*!
X .
/ d 6R *J' '
Q V(
%',
/ A9\ Y R .
2
# '/ 9' J
! ?! + ;! / *'
o *'5 /%!
I' yb- %d
# J/
# %!
%'9d / . J %@ 4 # '/ 9' J W *C 7
*T>% J\ #b'-0 .
! J! F ) % F.@ ! Q - !
X # @ ! ( F ' 9_'@
! %@ .L '
* C
.
I J 2 / #; : _ >
X .
Y> % ?'L Z% JC Q - '
X
%', 6 7 .C%/ Y ;5 g %! ' H0'( Qq C #dJ .A] N / %'
. ) ) =
*C
6R # %!
o
%d I' yb-
# J/
/ 6 7
%! YL > *! #5 > +$
. / *' .
#dJ F
# / <u> o'8 !
d y-0 #L % m& ! # > *T} .A]
%, .
% ) *! #L % C % )''; . *C / Y I'
! ! J, !
# 100
%! %!
~ _ %_' l
OLYMPUS CH30 Z
F B #9( '! Z & 6
/ . - 1
Vr m& C % ) % 0'! ! # C
#L % Z T
* @%, X Z 'T Q -
J, !
# 400
%! %!
W /
#L % m&
C
7 / 6 J *! ;
W ,MVD
%, . [ %
# 2}
- . %( [ % W /
0 . *\ %, . •'= *! 6 R / 6 7 #TAL : ;5 +
VIII-R%H 0 )
Y
%AT @ (
F v T
%L d I
\ #5 * @%, ' %!
X N
' ) !
%H 0 . = #dJ .A] / ! *9
-!
F A
%H 0
#L % )
# '/ 9' J (
6 *! %H
d VEGF
/ ! *9 *C .@%, %L
. = Z AL Y! L N #dJ .A]
./ #0-!
1
)'Js H 0
CD34 %
!
* Z T # ' C .T
# Qq C .A] N IA . 2!
/ .
) S T! %! # %!
#J'@ (
/ H
# H ! '!
6 7 /
* '!
! 7 %', *
' Y
€ d8 *! * ! %H <%&
'! %@ : b-0 F
/ #;
)_ >
: _
#L2$
#_/ ( [2$
%, . .
*Tx > N / %, # '/ 9' J
6% 4 C *! .An *
SPSS (11.5) @
!
d
Smirnov Kolmogorov-
Z % m
d ! #! %, '
t
#J; •+
05 /
P?0
%, 6 7 .
1
*;5 + )
; 30 .@ ! #;'A&
- B
30
> # 5 Y /
10 4' 2! T' # 5
>
20
> 4' 2! dJ5 # 5 / Q -
4\ C [ % C % '
C % %]C > ^ MVD
%, # %! • ^ .
JC T
# F) %'D
VJ l F
# 5
%, %
%L # %!
@%, J
! ^ A / #! MVD
. '!
> 4' 2! T' # 5 *! 2 A
*;5 +
%= >
Y /
M0 4 F
M1 4 F NJ(
FM2
M3 4 F
M4 '!
# 5 *! 2 A
> 4' 2! dJ5 Y /
L1 NJ(
F
L2 \
L3 4
! .
30 '!
# 5
* @%, %L # %!
20 '!
) 7 / 66 (%
% 10 '!
) 3 / 33 (%
! . ) ) % C
'!
17 ) % 0'!
71 Z
#J )'H ' ! 2
/ 36 Z
! . )'!
10 '!
> 4' 2! T' # 5
%!
#
* @%, %L 6
'!
) 60 (%
% 4 '!
) 40 (%
F ) % C
'! )
17 Z F ) % 0'!
) 71 Z
#J )'H '
3 / 37
! Z 1 )'Js 20
4' 2! dJ5 # 5 '!
* @%, %L # %! >
14 '!
) 70 (%
% 6 '!
) 30 (%
! . '! ) ) % C 17
! ) % 0' 68 Z
#J )'H ' ! 7
/ 35
! Z .
> # 5 *! 2 A '!
F ) % C ) % 0'!
4\ C [ % C % ' I' % *!
17 24 )'H '
8 /
±1 2 / 20
%, / I' % *! ) 5
F 12
7 /
±1 9 / 6
! . %D ' : d
)'! MVD
'! %, .@ ! > # 5 *! 2 A
#;'A&
#J;
!
) 001 /
P<0 ( ) 6 / 29
t= (.
> 4' 2! T' # 5 *! 2 A '! )'!
F
) % C ) % 0'!
4\ C [ % C % ' I' % *!
17
23 )'H ' ! 30
/ 20
# 5 *! 2 A '! )'!
> 4' 2! dJ5 F
I' % *!
17 24
! )'H ' 15 / 20
! .
*! 2 A '! %, )'!
AML
: d ' ALL
#J; MVD
A ) 83 / 0
P= .(
)'H ' )'Js
> # 5 %,% MVD
F
I' % *!
M0 23 F
M1 22 F 8 /
M2 18 F 22
FM3 M4 21
F 4 /
L1 20 F 1 /
L2 20
L3 20
! ) Z 1 (.
! 1 - MVD $
$ % &'()* + $
$ $
95
%
/ 0 % 1 2 %
3 MVD4() MVD 5 % MVD67 % &'()* 8 $ &'()* $ 3 &'()* 9) -
- 21,34
- 21,00 21,81 21,16 -
- - 16,25
- 21,00 18,98 18,97 -
- - 2,04
- 0,00 1,14 1,89 -
23,00 22,00 18,80 22,00 21,00 20,40 20,07 20,00
23,00 22,00 21,00 22,00 21,00 22,00 24,00 20,00
23,00 22,00 17,00 22,00 21,00 19,00 17,00 20,00
3,3 3,3 16,7
3,3 3,3 16,7 46,7 3,3
1 1 5 1 2 5 14
1
AML-M0 AML-M1 AML-M2 AML-M3 AML-M4
ALL-L1 ALL-L2 ALL-L3
) *! * !
* @%, %L *;5 + '! ; *C
> # 5 %,% #};!
F '9!
! C F
%, C% % ; / %,% J\ )'! ' %!
.
)'! g ) %!
L2
)M2
22 / 0
P= (
L1 )'!
M2
) 16 /
P=0 ( )'!
L1
! L2
) 72 /
P=0 (
#J; : d
%D '
! MVD
* ' . .
2 3
#
%C # %! #dT - / ! .
#_
! # '/ 9' J / ) #_
%H 0
Z T
%'D Z 'T
VIII-R CD31 F
CD34 F F
.... VEGF
. ) 15F14F4 (.
[ % ; W )
(MVD) 4\ C _ %_' T'@
J *! ~
# W , ';
/ .
d 6 W
/
%'D 5 # %'v tT -
#@ %,
* F%T(
MRI PET†
. .
%H W
%',
# % S%8 ' r( # @ !
f
%n
%'D
FVEGF bFGF
F Y
0 /
/ ?
‡.C2(
F Y
*Magnetic resonance imaging
†positron emission tomography
‡ Platelet-derived growth factors (PDGF)
Z '( / )'C 5% J F§
1 6 )'Js
**)'
! ' r( J )'! *C Z
J 9 % )
4 - 16 .(
%!
*;5 + g
Padro
_ W *! *C
F / 6 7 # '/ 9' J' 62
*! 2 A '!
! AML
%H 0 )'5 A %
Y @ / # %! %AT
)'H ' MVD
N C *
•
!
# J, !
500
%! %!
_ %_'
~ W ,
%, .
N g %!
'! MVD
%, % R ! AML
/ ) I' % *!
24
2 / 11 (
! 1
! )'Js
MVD F C
# C ) *C .@
(Remission))0' Y C
% 0'!
)0'
! Y C .
*C J @%, *7'
„ = F
#
%A
AML / !
) 17 .(
*! 2 A '! .9'! %H *;5 +
*! AML
%
20
*
#;'A&
d ! - B
%H 0
ULEX-E
Y
%! %AT @
[ % ; / #
/ % / * Z &
! *
%! . B Z &
[ % ; : x *! N %, '9 -
/ W , - B % 'T' .
* #;'A&
*
#
§Epidermal growth factor (EGF)
** Endostatin
( #! 6 dJ5 %D - B %', %! *C / Z #J( '
! / W , #dJ F
Q -
%, .
# 5 [ % ; N g %!
* > 4' 2! T'
#;'A&
I' % *!
3 / 8 3 / 4
!
ULEX-E %H 0 6
/ 8 9 / 4
!
%H 0 Y
@
! %AT
* / %, )'! <2 $ ) *C .
#J; %D
# 5 %, % )'! !
*+! )'J\
! * ' . ) 18 .(
%!
*;5 + g ' F#! J %C %H
MVD 7J
!
Fas-ligand (FasL) %H 0
Y
%AT @ - B .@ ! VEGF
43
'!
> 4' 2! T' # 5 *! 2 A )'Js
18
*
#;'A&
/ #!
MVD . N )'H '
! • C J, !
# 400
%! %!
_ %_' W , ~
%, .
! '; * % *
'! #b-0 &
% R ! AML
%, %@
/
! ! F
C '
# .@
MVD .
!
Y %H 0
%AT @
AML '!
%, / I' % *!
3 /
±14 9 / 31
8 /
±2 1 / 9
!
FasL %H 0 I' % *!
2 /
±27 1 / 55
3 /
±10 8 / 12
! . / %Cq *5 *C &
!
* .
%H 0
!
*
#J; <2 $ %H _ ! * @ C .
%!
*;5 + g
*+!
' )'!
x ; MVD
%, 0 - B . 2!
) 19 (
# x
*C
*;5 +
Padro
*+! )'J\
W , 0 ) 17 (.
%!
*;5 + g )'\
MVD ' #9( '!
- B
T'@
400
%! %!
_ %_'
#(
F )'
&
B %'r m VEGF
%, # %! - .
%!
' N g
'! MVD
) 82 / 22 (
!
*
&
%, %@ % 0'! #b-0 /
) 17 / 7 (
! . 6 HJ
)0'
MVD ' Z ;
57 / 8 6 HJ !
' *! 6 # 5
83 MVD
/ 21 : d *C !
! # J\
./ '! MVD
.
*;5 + g %!
MVD '
ALL Z ; 09 /
ANLL 23 Z ;
37 / 22 0 0 %, ) )'! # J\ : d *C ! 1
%,% )'! )'Js : d ' AML
./
.
%!
*+! *;5 + g ' )'!
MVD
, 0 - B . 2! x ;
% ) 20 .(
. y-0 *C &
Y ;5 @ Y'5 *!
)''; %!
FMVD
! /
*
* @ C o
)' 8 '
J, ! _ %_' #
d #(
>
wR _ %_' l
! ~
*
. : d %H _ ! * @ C
1
) %! J!
! *C . # !
* .
! # C
%H _
: d .
*;5 + N
%= >
: ;5 + *! 0 '9!
! %$ *;5 + { b-! / 1
' *C : x ) !
> # 5 MVD
F
!
*
% 0'! #b-0 &
%, %@
/
! .
%, )'! # J\ : d
T' 4' 2! dJ5 > # 5
)'! )'Js 4' 2!
./ %,%
.
# 5 *! … (
„ = !
)
%'D
' '5 ( )' 8 #};! o '
%L # %!
. * @%,
Steins . _
25
%
# … (
!
W , ' '5
%C ) 21 .(
4 5
> # 5
* @ @
!
*
#b-0 &
%, %@ % 0'!
/
!
%, )'! # J\ : d
4' 2! T' 4' 2! dJ5 > # 5 .
*;5 + %= >
Q - I J Y8 W%! 4 '! %
X .@%, %L # '/ 9' J ' .
. # !
%@ /%! *'
?'L )' - % ' %
! MVD
*
$ . 1
)'Js
%'H'(
^ A '!
! MVD
' '(
# ,
.$ $ )/
.
,0 .
*60
! #0 ( |%& *! ^ !% *;5 + ) Yx > N
" J
# 5 # %!
! *9 >
.@ !
#;'A&
- B
"
. / ! *C 84356
*! 0 #_/ ( 6 T H0 #0 ( . ; <%&
. ' I b
1 6% 8 . ; *T' ) !
# %_0 H0 #0 ( 6% 8 /
%, .
#! _ : > )'Js
† JC C 6% 8
I' -!
'! # J/
K L ) N ( F
% + L !
%! $ X *' *C
6R '
.
* / _ F
# # L
%, .
73 8 :
1- Greer JP, Rodgers GM, Paraskevas F, Foerster J, Lukens JN, Glader B. Wintrob's Clinical Hematology. 11thed.
Philadelphia: Lippincott Williams & Wilkins; 2004: p: 1916.
2- Hutchison RE, Abraham NZ. Leukocytic Disorders .In: McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Pennsylvania: Elsevier Saunders; 2007.p: 565.
3- Ries LAG, Esiner MP , Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER Cancer Statistics Review, 1973- 1999. Bethesda, MD: National cancer institute, 2002; 1-23.
4- Ministry of Health & Medical Education, Center for disease control, Cancer Control Office: Iranian annual cancer registration report 2003. 2005; 2-3.
5- Moehler TM, Ho AD, Goldschmidt H, Barlogie B: Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol. 2003; 45 (3): 227-44.
6- Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathologic basis of disease .7th ed. Pennsylvania: Elsevier Saunders; 2004. p: 309.
7- Guo J, Higashi K, Ueda Y, Oguchi M, Takegami T, Toga H, et al: Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med. 2006; 47 (3): 419-25.
8- Sadeghian MH, Sharifi N, Shakeri MT. Microvessel density in ductal carcinoma of breast and comparison with normal breast tissue. Iranian J Med Sci. 2006; 4 (8): 246-51.
9- Javadi P, Haeri H. Tumor angiogenesis in colorectal cancer, correlation with tumor extension and invasion. J Tehran Faculty of Med. 2001; 4 (59): 50-56.
10- Tavangar SM, Hojjati SR, Larijani B. The study of angiogenesis in malignant thyroid neoplasms with immunohistochemistry method. Iranian J Endocrinol Metabol. 2005; 27 (7): 213-16.
11- Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997; 150 (3): 815-21.
12- Rabitsch W, Sperr WR, Lechner K, Chott A, Prinz E, Valent P, et al. Bone marrow microvessel density and its prognostic significance in AML. Leuk Lymphoma. 2004; 45 (7): 1369-73.
13- Mesters RM, Padró T, Steins M, Bieker R, Retzlaff S, Kessler T, et al. Angiogenesis in patients with hematologic malignancies. Onkologie. 2001; 24 Suppl 5: 75-80.
14- Panteli K, Zagorianakou N, Bai M, Katsaraki A, Agnantis NJ, Bourantas K.1Hematology:Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. Eur J Haematol. 2004; 72 (6): 410-15.
15- Kuzu I, Beksac M, Arat M, Celebi H, Elhan AH, Erekul S. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma. 2004; 45 (6): 1185-90.
16- Wrobel T, Mazur G, Kapelko K, Kuliczkowski K. Endostatin serum level in acute myeloid leukemia. Neoplasma.
2005; 52 (2): 182-84.
17- Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of
patients with acute myeloid leukemia. Blood. 2000; 95 (8): 2637-44.
18- Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia, Blood. 2000; 95 (1): 309-13.
19- Lee JJ, Chung IJ, Park MR, Ryang DW, Park CS, Kim HJ. Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leuk Res. 2001; 25 (12): 1067-73.
20- Ye XJ, Wang LJ, Lin MF, Ding W. The clinical significance of angiogenesis in the bone marrow of acute leukemia patients . Zhonghua Nei Ke Za Zhi. 2003; 42 (7): 486-89.
21- Steins MB, Bieker R, Padro T, Kessler T, Kienast J, Berdel WE, et al. Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma. 2003; 44 (9): 1489-93.
Title: Angiogenesis in acute leukemia and comparing it with normal bone marrow Authors: MH.Sadeghian1,N. Sharifi2,H. Ayatallahi3, M. Khajeh Daloei4
Abstract:
Background and Aim: Angiogenesis is essential in the progression and metastasis of solid tumors. It has been proved that increase in angiogenesis within primary solid tumors is actually associated with nodal metastasis and risk prognosis of some malignancies. In contrast, regarding hematologic neoplasms very limited studies have been done. The goal of the present study was to determine MVD (Microvessel density) in acute leukemia and compare it with MVD in normal tissues.
Materials and Methods: In this study 30 cases with acute leukemia and 30 normal controls were selected.
These had been diagnosed and archived in the pathology department of Mashhad Ghaem hospital .Their blocks and slides were prepared and examined. After their final approving, the paraffin blocks were thinly sliced and the slices were immunohistochemically stained for VEGF (Vascular Endothelial Growth Factor) Immunohistochemical slides were evaluated for hot spots of MVD in the tissue in the microscopic field of vision with 400 times magnification.
Results: MVD or angiogenesis in acute leukemia was 20.2% which was obviously more than that in the controls (6.9%).The difference between the two groups was statistically significant (P<0.001).
Conclusion: Angiogenesis in acute leukemia is significantly higher compared with the controls (who had normal tissues).But there was no significant difference between acute myeloid leukemia and acute lymphoblastic leukemia.
Key Words: Acute Leukemia; Microvessel density (MVD); Immunohistochemistry; Angiogenesis
1Corresponding author, Assistant Professor, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences (Cooperating in the Blood Bank and Serology Units). Mashhad, Iran sadeghianmh@mums.ac.ir
2Associate Professor, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3Assistant Professor, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4Associate Professor, Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
